Accueil・Liste d'Actions・CRISPR Therapeutics AG

CRISPR Therapeutics AG

Fermé

SecteurSoins de santé

58.76 4.3

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

55.99

Max

56.94

Chiffres clés
By Trading Economics
Revenu	-91M -214M
Ventes	8.7M 10M
BPA	-0.94
Marge bénéficiaire	-2,102.79
Employés	393
EBITDA	7.3M -110M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+30.1% upside

Dividendes
By Acuity
Prochains Résultats	9 nov. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	519M 5.1B
Ouverture précédente	54.46
Clôture précédente	58.76

Sentiment de l'Actualité

By Acuity

26%

74%

28 / 339 Classement par Healthcare

CRISPR Therapeutics AG Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

19 sept. 2026, 00:02 UTC

Correlated Moves

CRISPR Therapeutics AG is advancing in after-market trading, likely in sympathy with Editas Medicine Inc, amid broader economic concerns.

18 sept. 2026, 23:01 UTC

CRISPR Therapeutics AG is advancing in after-market trading, moving higher alongside the broader market, following a peak return earlier in the session.

17 sept. 2026, 23:51 UTC

CRISPR Therapeutics AG declined modestly during after-market hours on Thursday, breaking a recent trend of higher daily closes.

16 sept. 2026, 23:16 UTC

CRISPR Therapeutics AG is declining in after-market hours, trading near the lower end of its one-month range and below its 20-day moving average.

15 sept. 2026, 23:01 UTC

CRISPR Therapeutics AG shares are higher in after-market hours, reflecting overall market momentum despite a decline in the New York Empire State Manufacturing Index.

14 sept. 2026, 23:01 UTC

CRISPR Therapeutics AG shares are higher in after-market trading, reflecting a strong performance despite declining major indices and rising crude oil prices.

11 sept. 2026, 23:01 UTC

CRISPR Therapeutics AG shares are higher in after-market trading, influenced by a narrower-than-expected U.S. budget deficit of $167 billion for August.

10 sept. 2026, 20:07 UTC

CRISPR Therapeutics AG shares are lower amid a broader market decline following the European Central Bank's interest rate hike and rising Treasury yields.

8 sept. 2026, 20:07 UTC

CRISPR Therapeutics AG shares are lower today, marking four consecutive sessions of declines amid market speculation on potential interest rate hikes.

4 sept. 2026, 23:37 UTC

Correlated Moves

CRISPR Therapeutics AG shares rose in after-market trading, reflecting a modest increase since Friday's close, aligning with Beam Therapeutics' sector performance.

3 sept. 2026, 23:56 UTC

CRISPR Therapeutics AG shares are lower in after-hours trading, continuing a decline since Thursday's close, despite broader market gains. No specific news was identified.

2 sept. 2026, 19:46 UTC

CRISPR Therapeutics AG shares are lower today, continuing a four-day decline amid rising U.S. Treasury yields and inflationary pressures affecting the biotechnology sector.

1 sept. 2026, 23:06 UTC

CRISPR Therapeutics AG shares are lower in after-market trading, with no specific news identified to explain the movement. The stock has declined in three consecutive sessions.

31 août 2026, 23:06 UTC

CRISPR Therapeutics AG shares are higher in after-market trading, reflecting stable performance amid broader economic sentiment and expectations for a potential rate hike.

29 août 2026, 00:02 UTC

CRISPR Therapeutics AG shares are lower in after-market hours, continuing a trend of notable weakness amid rising market expectations for an interest rate hike.

28 août 2026, 22:51 UTC

CRISPR Therapeutics AG shares are lower in after-market hours, continuing a trend of weakness since Friday's close with no specific news identified.

27 août 2026, 23:02 UTC

CRISPR Therapeutics AG shares are higher in after-market trading, reflecting overall strength despite a slight pullback from earlier highs. No specific news was identified.

26 août 2026, 23:02 UTC

CRISPR Therapeutics AG shares are higher in after-market hours, maintaining strength above the 20-day moving average and near the upper end of their one-month range.

25 août 2026, 23:06 UTC

CRISPR Therapeutics AG shares are lower in after-market hours, reflecting a decline after Tuesday's close, despite a significant gain over the past month.

24 août 2026, 23:01 UTC

Shares of CRISPR Therapeutics AG declined in after-market trading, despite briefly recovering earlier in the session. The stock remains above its 20-day moving average.

21 août 2026, 23:36 UTC

CRISPR Therapeutics AG shares are higher in after-market trading, maintaining a position above the 20-day moving average and near the one-month range's upper end.

20 août 2026, 19:51 UTC

Correlated Moves

Shares lower today amid broader market pressures; SPDR S&P Biotech declines.

19 août 2026, 23:01 UTC

CRISPR Therapeutics AG shares are lower in after-market trading, continuing a decline since Wednesday's close amid notable volatility.

18 août 2026, 22:16 UTC

CRISPR Therapeutics AG shares are lower in after-market trading, reflecting unusual downward momentum amid broader market declines in major U.S. tech stocks.

17 août 2026, 23:06 UTC

Correlated Moves

CRISPR Therapeutics AG shares are lower in after-market trading, reflecting broader market sentiment affecting small-cap stocks amid a slight decline in the Russell 2000 Index.

14 août 2026, 19:16 UTC

CRISPR Therapeutics AG shares are lower today amid broader investor caution following a decline in U.S. retail sales for July.

13 août 2026, 23:46 UTC

Correlated Moves

CRISPR Therapeutics AG shares are higher in after-market trading, reflecting a positive trend in the biotechnology sector amid favorable economic conditions.

11 août 2026, 19:21 UTC

CRISPR Therapeutics AG shares are trading higher amid rising oil prices and inflation concerns ahead of upcoming U.S. inflation data. No specific news was identified.

10 août 2026, 23:06 UTC

No specific news was identified for CRISPR Therapeutics AG, which traded roughly flat during after-market hours, remaining near the upper end of its one-month range.

7 août 2026, 20:06 UTC

News

Correlated Moves

Social Media

CRISPR Therapeutics AG is gaining amid positive social media sentiment and bullish chart patterns, aligning with the upward trend in the ARK Genomic Revolution ETF.

Comparaison

Variation de prix

CRISPR Therapeutics AG prévision

Objectif de Prix

By TipRanks

30.1% hausse

Prévisions sur 12 Mois

Moyen 73.583 USD 30.1%

Haut 110 USD

Bas 45 USD

Basé sur 13 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

13 ratings

Achat

Maintien

Vente

Basé sur 13 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

28 / 339Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos CRISPR Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.